Lyme disease overview

Revision as of 18:09, 7 August 2017 by Anmol Pitliya (talk | contribs)
Jump to navigation Jump to search
https://https://www.youtube.com/watch?v=rOQvpcpxbCs%7C350}}

Lyme disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Epidemiology and Demographics

Causes

Differentiating Lyme disease from other Diseases

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

ECG

X-ray

CT scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Sudies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Lyme disease overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lyme disease overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lyme disease overview

CDC on Lyme disease overview

Lyme disease overview in the news

Blogs on Lyme disease overview

Directions to Hospitals Treating Lyme disease

Risk calculators and risk factors for Lyme disease overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

Lyme disease is an emerging infectious disease caused by spirochete bacteria from the genus Borrelia.[1] The vector of infection is typically the bite of an infected black-legged or deer tick, but other carriers (including other ticks in the genus Ixodes) have been implicated.[2] Borrelia burgdorferi is the predominant cause of Lyme disease in the US and Borrelia afzelii and Borrelia garinii are in Europe.

The disease presentation varies widely, and may include rash and flu-like symptoms in its initial stage, then musculoskeletal, arthritic, neurologic, psychiatric and cardiac manifestations. In a majority of cases, symptoms can be eliminated with antibiotics, especially if treatment begins early in the course of illness. Late or inadequate treatment often leads to "late stage" Lyme disease that is disabling and difficult to treat. Controversy over diagnosis, testing and treatment has led to two different standards of care.[3][4]

Historical Perspective

In 1883, Alfred Buchwald was the first to describe a condition associated with Lyme disease which is now known as acrodermatitis chronica atrophicans. Arvid Afzelius first observed ring-like lesions, now known as Erythema migrans, and associated the rash with tick bites. In the United States, Lyme disease was not recognized until 1975, when a cluster of cases was identified in three towns in Southeastern Connecticut (including towns Lyme and Old Lyme), which gave Lyme disease its popular name. In 1981, the infectious agent (a spirochete) was isolated by Willy Burgdorfer, a researcher at the National Institutes of Health, from the midgut of Ixodes ticks. The spirochete was named Borrelia burgdorferi in honor of Willy Burgdorfer.

Classification

Lyme disease can be classified into three stages. The first stage is localized Lyme disease, the second is disseminated Lyme disease, and the third is late disseminated Lyme disease. During stage 1, the patient can develop erythema migrans rash. Ten to twenty percent of the patients who have Lyme disease can develop post treatment Lyme disease syndrome. There are various genospecies of Borrelia burgdorferi sensu lato complex that can cause Lyme disease. A novel spirochete, Borrelia mayonii, has been recently discovered to be responsible for Lyme disease.

Pathophysiology

Lyme disease is caused by Borrelia burgdorferi and is transmitted by tick named Ixodes scapularis. Ticks can attach to any part of the human body but are often found in hard-to-see areas such as the groin, armpits, and scalp. In most cases, the tick must be attached for 36 to 48 hours or more before the Lyme disease bacterium can be transmitted.

Epidemiology and Demographics

Lyme disease is the most common tick borne disease in North America and the the ratio of Lyme disease infection is 7.9 cases for every 100,000 persons. The number of people diagnosed with Lyme disease each year in the United States is around 300,000. This disease is concentrated heavily in the northeast and upper midwest.

Causes

Lyme disease is caused by Gram-negative spirochetal bacteria from the genus Borrelia. At least 37 Borrelia species have been described, 12 of which are Lyme related. The Borrelia species known to cause Lyme disease are collectively known as Borrelia burgdorferi sensu lato, and have been found to have greater strain diversity than previously estimated.[5]

Until recently it was thought that only three genospecies caused Lyme disease: B. burgdorferi sensu stricto (predominant in North America, but also in Europe), B. afzelii, and B. garinii (both predominant in Eurasia). However, newly discovered genospecies have also been found to cause disease in humans.

Differentiating Lyme from other Disease

The differential diagnosis of Lyme's disease include Babesiosis, Leptospirosis, Mononucleosis, viral Meningitis and chronic diseases such a SLE, Fibromyalgia and Chronic fatigue syndrome.

Risk Factors

As a tick-borne disease, an individual is at a heightened risk of contracting Lyme disease when traveling or residing within endemic regions. Risk within endemic regions will heighten during the spring and summer months, with peaks in June and July. Other factors that may increase the risk of contracting Lyme disease include owning a domesticated animal such as a dog or cat; As both of these pets may be potential hosts for a blacklegged tick. In summary, individuals who spend much of their time outdoors and/or have pets that go outdoors in endemic regions, are at a higher risk of contracting tick-borne diseases. [6]

Natural History, Complications and Prognosis

Lyme disease is effectively managed by prompt treatment. Prognosis is affected by failure to treat in a timely manner as well as simultaneous infections with other tick-borne diseases. Lyme disease can cause neurological complications such as facial paralysis and carditis.

Diagnosis

Due to the difficulty in culturing Borrelia bacteria in the laboratory, diagnosis of Lyme disease is typically based on the clinical exam findings and a history of exposure to endemic Lyme areas.[1] The EM rash, which does not occur in all cases, is considered sufficient to establish a diagnosis of Lyme disease even when serologies are negative.[7][8] Serological testing can be useful, but is not diagnostic.[1]

Clinicians who diagnose strictly based on the U.S. Centers for Disease Control (CDC) Case Definition for Lyme are in error, as the CDC explicitly states that this definition is intended for surveillance purposes only, and is "not intended to be used in clinical diagnosis."[9][10]

Importantly, virtually no controlled studies of late lyme encephalopathy have been performed, and the CDC diagnostic criteria were not formulated for use on this entity. Once lyme disease is well established in the brain, it can occur as a very disabling diffuse encephalopathy which however is difficult to diagnose using standard serological or intrathecal testing for reasons outlined below. Lyme is a deep tissue infection and by the time encephalopathy is established, few if any CSF antibodies can be detetected, and PCR is unreliable. Seronegative disease can occur for the same reason that this phenomenon occurs in neurosyphilis, with incomplete or intercurrent antibiotic treatment abrogating the serum antibody response, but not eliminating the infection.

It is in this context that advanced imaging studies like SPECT or PET can provide objective evidence of global brain dysfunction. Resolve is often made to neuropsychological testing, but a normal result does not rule out the illness, which can be very subtle and manifest as a disabling mood disorder accompanied by massive and debilitating fatigue, with few objective signs.

Diagnosis of late-stage Lyme disease it is often difficult due to the multi-faceted appearance which can mimic symptoms of many other diseases. For this reason Lyme has often been called the new "great imitator".[11] Lyme disease may be misdiagnosed as Multiple sclerosis, Rheumatoid arthritis, Fibromyalgia, Chronic fatigue syndrome (CFS), or other Autoimmune and Neurodegenerative diseases.

History and Symptoms

Lyme disease is divided into 3 stages and symptoms are stage specific. Symptoms include "bulls-eye" rash, with accompanying fever, malaise, and musculoskeletal pain, (arthralgia or myalgia. It can progress to cardiovascular or neurological complications.

Physical Examination

The physical examination of lyme disease is necessary for the diagnosis. Fever andtarget shaped rash are commonly seen on physical examination. Cardiac examination is significant for carditis.

Laboratory Findings

Laboratory blood tests are helpful if used correctly and performed with validated methods. Laboratory tests are not recommended for patients who do not have symptoms typical of Lyme disease. Polymerase chain reaction (PCR) tests for Lyme disease have also been developed to detect the genetic material (DNA) of the Lyme disease spirochete.

Other Imaging Findings

Single photon emission computed tomography is one of the major other imaging modalities of Lyme disease. In Lyme patients cerebral hypoperfusion of frontal subcortical and cortical structures has been reported.

Treatment

Medical Therapy

The mainstay of therapy for lyme disease is antimicrobial therapy. Antimicrobial therapy may include either doxycycline, amoxicillin, cephalosporins, or macrolides. Individuals who remove attached ticks should be monitored closely for signs and symptoms of tick-borne diseases for up to 30 days.

Primary Prevention

Primary prevention of Lyme disease involves reducing exposure to ticks. Scientists have been developing all-natural chemical compounds made from plants that can repel or kill ticks. A Lyme disease vaccine is no longer available.

Secondary Prevention

The secondary prevention of Lyme disease is similar to its primary prevention.

References

  1. 1.0 1.1 1.2 Ryan KJ, Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed. ed.). McGraw Hill. pp. 434&ndash, 7. ISBN 0838585299.
  2. Johnson RC (1996). "Borrelia". Baron's Medical Microbiology (Baron S et al, eds.) (4th ed. ed.). Univ of Texas Medical Branch. ISBN 0-9631172-1-1.
  3. Johnson L (2005-02). "Lyme disease: two standards of care". International Lyme and Associated Diseases Society. Retrieved 2007-08-21. Check date values in: |date= (help)
  4. Johnson L, Stricker R (2004). "Treatment of Lyme disease: a medicolegal assessment". Expert Rev Anti Infect Ther. 2 (4): 533–57. PMID 15482219.
  5. Bunikis J, Garpmo U, Tsao J, Berglund J, Fish D, Barbour AG (2004). "Sequence typing reveals extensive strain diversity of the Lyme borreliosis agents Borrelia burgdorferi in North America and Borrelia afzelii in Europe" (PDF). Microbiology. 150 (Pt 6): 1741–55. PMID 15184561.
  6. General Information (2015). http://www.cdc.gov/ticks/index.html Accessed on December 30, 2015
  7. Brown SL, Hansen SL, Langone JJ (1999). "Role of serology in the diagnosis of Lyme disease". JAMA. 282 (1): 62–6. PMID 10404913.
  8. Hofmann H (1996). "Lyme borreliosis--problems of serological diagnosis". Infection. 24 (6): 470–2. PMID 9007597.
  9. "Lyme Disease (Borrelia burgdorferi): 1996 Case Definition". CDC Case Definitions for Infectious Conditions under Public Health Surveillance. 1996. Retrieved 2007-08-23.
  10. "CDC Testimony before the Connecticut Department of Health and Attorney General's Office". CDC's Lyme Prevention and Control Activities. 2004-01-24. Retrieved 2007-08-23.
  11. Pachner AR (1989). "Neurologic manifestations of Lyme disease, the new "great imitator"". Rev. Infect. Dis. 11 Suppl 6: S1482–6. PMID 2682960.


Template:WikiDoc Sources